1 Weeks KS,Kahl AR,Lynch CF,et al.Racial/ethnic differences in thyroid cancer incidence in the United States,2007-2014[J].Cancer,2018,124(7):1483-1491. 2 李诚,兰莉,杨超,等.2015-2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J].实用肿瘤学杂志,2019,33(1):68-72. 3 Masudo K,Suganuma N,Nakayama H,et al.EZH2 Overexpression as a Useful prognostic marker for aggressive behaviour in Thyroid cancer[J].Vivo,2018,32(1):25-31. 4 Hamivand Z,Haddadi G,Fardid R.Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated Thyroid cancer[J].J Med Phys,2018,43(1):41-45. 5 Bates MF,Lamas MR,Randle RW,et al.Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?[J].Surgery,2018,163(1):118. 6 张波,徐景竹,吴琼.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:超声部分[J].中国癌症杂志,2016,26(1):19-24. 7 董文武,张浩.2018年版日本《甲状腺肿瘤诊疗指南》外科治疗部分更新解读[J].中国实用外科杂志,2019,39(12):1260-1264. 8 Yeh CC,Su FH,Tzeng CR,et al.Women with adenomyosis are at higher risks of endometrial and thyroid cancers:A population-based historical cohort study[J].PLoS One,2018,13(3):e0194011. 9 邢家亮,李鲁传.难治性甲状腺癌的靶向治疗[J].中国医师进修杂志,2018,41(11):961-963. 10 Berdelou A,Lamartina L,Klain M,et al.Treatment of refractory thyroid cancer[J].Endocr Relat Cancer,2018,25(4):209-223. 11 陈志丹,陈德杰.甲状腺癌术后复发相关危险因素分析及复发预测模型构建[J].东南大学学报(医学版),2015,34(1):92-95. 12 赵乌云,张雅峰.大剂量131I治疗对分化型甲状腺癌术后清除残余甲状腺及转移灶的效果与影响因素[J].内蒙古医科大学学报,2019,41(3):253-255. 13 Ryu YJ,Kang SJ,Cho JS,et al.Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer[J].Medicine,2018,97(51):e13435. 14 Reese J,Chebolu A,Shen YJ,et al.Case report:diffuse metastatic infiltration of the thyroid by esophageal adenocarcinoma mimicking non-neoplastic thyroid disease[J].Radiol Case Rep,2018,13(1):108-111. 15 Seo JW,Han K,Lee J,et al.Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma[J].PLoS One,2018,13(3):e0193883. 16 Vuttariello E,Biffali E,Pannone R,et al.Rapid methods to create a positive control and identify the PAX8/PPARγ rearrangement in FNA thyroid samples by molecular biology[J].Oncotarget,2018,9(27):19255-19262. 17 Eliza S,Suyash D,Pratibha S,et al.Secondary salivary gland malignancy in thyroid cancer:A United States Population Based Study[J].J Clin Med Res,2018,10(7):601-605. 18 何东生,曾先捷.甲状腺癌患者预后风险模型的构建[J].实用癌症杂志,2019,34(11):1865-1868. 19 Zhang HM,Xie PL,Li ZY,et al.A nomogram for predicting the HER2 status in female patients with breast cancer in China:a nationwide,multicenter,10-year epidemiological study[J].Diagn Pathol,2019,14(1):35. |